Literature DB >> 11687020

Antibiotics for spontaneous bacterial peritonitis in cirrhotics.

K Soares-Weiser1, M Brezis, L Leibovici.   

Abstract

BACKGROUND: Spontaneous bacterial peritonitis is mainly a complication of cirrhotic ascites that occurs in the absence of any intra-abdominal, surgically treatable source of infection. Antibiotics have been recommended as the mainstay treatment for spontaneous bacterial peritonitis. However, this recommendation is not based on convincing evidence. It has been proposed that treatment should cover Gram-negative enteric bacteria and Gram-positive cocci, that are responsible for up to 90% of cases.
OBJECTIVES: To evaluate the effectiveness and safety of different types and ways of antibiotic therapy for spontaneous bacterial peritonitis in cirrhotic patients. SEARCH STRATEGY: Electronic searches on the Cochrane Library (Issue 3, 2000), the Cochrane Hepato-Biliary Group Trials Register (March 2000), EMBASE (1980-2000), MEDLINE (1966-2000); scanning the references of all identified studies; contacting the first author of each included trial. SELECTION CRITERIA: Randomised trials comparing different types of antibiotics for spontaneous bacterial peritonitis in cirrhotic patients. DATA COLLECTION AND ANALYSIS: Data were independently extracted by two reviewers. Relative risks or weighted mean differences, with their 95% confidence intervals were estimated using 'intention-to-treat' analyses. MAIN
RESULTS: Nine trials dealing with 684 patients diagnosed with spontaneous bacterial peritonitis were included. No placebo-controlled trial was found. Each of the included trials compared different antibiotics, and no meta-analysis could be performed. We were unable to establish the optimal dose or duration of antibiotic therapy and found no convincing evidence that cefotaxime is more effective than ampicillin-tobramycin or that oral quinolones should be recommended for patients with less severe manifestations of the disease. REVIEWER'S
CONCLUSIONS: This review provides no clear evidence for the treatment of cirrhotic patients with spontaneous bacterial peritonitis. Until large, well-conducted, trials provide adequate evidence, treatment must be based on clinical experience.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11687020     DOI: 10.1002/14651858.CD002232

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  7 in total

Review 1.  Evidence based case report. Antibiotic treatment for spontaneous bacterial peritonitis.

Authors:  K Soares-Weiser; M Paul; M Brezis; L Leibovici
Journal:  BMJ       Date:  2002-01-12

Review 2.  Mortality from cirrhosis: lack of progress over the last 35 years.

Authors:  C Gluud
Journal:  Gut       Date:  2005-11       Impact factor: 23.059

Review 3.  Spontaneous bacterial peritonitis.

Authors:  Anastasios Koulaouzidis; Shivaram Bhat; Athar A Saeed
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

Review 4.  Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients.

Authors:  Norberto C Chavez-Tapia; Karla Soares-Weiser; Mayer Brezis; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2009-01-21

5.  Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis.

Authors:  Rohit Loomba; Robert Wesley; Andrew Bain; Gyorgy Csako; Frank Pucino
Journal:  Clin Gastroenterol Hepatol       Date:  2008-12-27       Impact factor: 11.382

6.  Bacterial infections in acute variceal hemorrhage despite antibiotics-a multicenter study of predictors and clinical impact.

Authors:  Stephen Lee; Lynora Saxinger; Mang Ma; Verónica Prado; Joaquin Fernández; Deepali Kumar; Juan Gonzalez-Abraldes; Adam Keough; Ravin Bastiampillai; Michelle Carbonneau; Javier Fernandez; Puneeta Tandon
Journal:  United European Gastroenterol J       Date:  2017-04-04       Impact factor: 4.623

Review 7.  Children in reviews: methodological issues in child-relevant evidence syntheses.

Authors:  Kristie Cramer; Natasha Wiebe; Virginia Moyer; Lisa Hartling; Katrina Williams; George Swingler; Terry P Klassen
Journal:  BMC Pediatr       Date:  2005-09-21       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.